Department of Plastic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Wuhan Clinical Research Center for Superficial Organ Reconstruction, Wuhan, 430022, People's Republic of China.
Int J Nanomedicine. 2024 Oct 17;19:10551-10568. doi: 10.2147/IJN.S477109. eCollection 2024.
Delayed diabetic wound healing is one of the clinical difficulties, the main reason is the limited angiogenesis ability. Deferriamine (DFO) is an iron chelating agent that can induce angiogenesis, but its application is limited due to its short half-life. Increasing the load and slow release performance of desferriamine is beneficial to accelerate diabetic wound healing.
In this study, we developed collagen (Col)-graphene oxide (GO) and (1% w/w) DFO-loaded nanofiber electrospinning scaffolds (DCG) using the electrospinning technique. We tested the physicochemical properties, drug release performance, and vascularization biological function of the scaffolds, and finally evaluated the promotion of full-thickness wound healing in the diabetic rat models.
The results showed that DCG scaffolds have good mechanical properties and water-holding capacity and can release DFO continuously for 14 days. In vitro, the novel DCG scaffold exhibited good biocompatibility, with the up-regulation at the gene level of VEGF and its regulator HIF-1α, promoters of angiogenesis. This was verified in vivo, as the scaffold enhanced granulation tissue formation and improved neovascularization, thereby accelerating wound healing when applied to full-thickness defects on the back of diabetic rats.
The DCG nanofiber scaffold prepared in this study has good biocompatibility and vascularization ability, and improves the microenvironment in vivo, and has a good application prospect in diabetic wound repair.
糖尿病创面愈合延迟是临床面临的难题之一，主要原因是其血管生成能力有限。去铁胺（DFO）是一种铁螯合剂，能诱导血管生成，但由于半衰期短，其应用受到限制。增加去铁胺的载药量和缓控释性能有利于加速糖尿病创面愈合。
本研究采用静电纺丝技术制备了胶原（Col）-氧化石墨烯（GO）和（1% w/w）载去铁胺纳米纤维支架（DCG）。我们测试了支架的理化性质、药物释放性能和血管化生物学功能，并最终评估了其在糖尿病大鼠模型中促进全层创面愈合的作用。
结果表明，DCG 支架具有良好的力学性能和保水能力，能持续释放 DFO 达 14 天。体外实验表明，新型 DCG 支架具有良好的生物相容性，能上调血管生成的 VEGF 及其调节因子 HIF-1α、血管生成启动子的基因水平。这在体内得到了验证，因为支架增强了肉芽组织的形成和新血管的生成，从而加速了糖尿病大鼠背部全层缺陷的愈合。
本研究制备的 DCG 纳米纤维支架具有良好的生物相容性和血管生成能力，改善了体内微环境，在糖尿病创面修复中具有良好的应用前景。
